News
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...
California pension fund CalPERS, the second-largest public purchaser of health benefits in the U.S., announced on Tuesday ...
The company will offer a generic version of semaglutide in the country after Novo Nordisk let its patent expire there. Hims & ...
Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...
22h
Stockhead on MSNBig pharma takes notice as Novo Nordisk puts Clever Culture’s APAS to the testClever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...
Explore more
Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...
8hon MSN
Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.
NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...
In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...
Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...
6h
Zacks.com on MSNHow Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results